Henry E. Mark
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Henry E. Mark has a total of 203 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey Victor Lazarus
CUNY Graduate School of Public Health and Health Policy (CUNY SPH), New York, New York, USA
13 shared publications - Jorn Markus Schattenberg
Department of Medicine II, Saarland University Medical Center, Saarland University, 66421 Homburg, Germany
6 shared publications - Vincent Wai-Sun Wong
Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
6 shared publications - Alina M. Allen
Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
4 shared publications Emmanuel A. Tsochatzis
University College London Institute for Liver and Digestive Health, Royal Free Hospital, London, United Kingdom
4 shared publicationsHannes Hagström
Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
4 shared publications
Latest Publications
- Open Access
- 25 May 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 65, 101713
Assessing Europe's policy readiness to confront the MASLD/MASH public health threat
- 25 May 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 65, 101713
Open AccessAssessing Europe's policy readiness to confront the MASLD/MASH public health threat
- Open Access
- 30 April 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (5)
Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction–associated steatotic liver disease
Background: Noninvasive tests (NITs) are used to risk-stratify metabolic dysfunction–associated steatotic liver disease. The aim was to survey global patterns of real-world use of NITs. Methods: A 38-item survey was designed by the Global NASH Council. Providers were asked about risks for advanced fibrosis, which NITs (cutoff values) they use to risk-stratify liver disease, monitor progression, and which professional guidelines they follow. Results: A total of 321 participants from 43 countries completed the survey (54% hepatologists, 28% gastroenterologists, and 18% other). Of the respondents, 85% would risk-stratify patients with type 2 diabetes, obesity (82%), or abnormal liver enzymes (73%). Among NITs to rule out significant or advanced fibrosis, transient elastography (TE) and fibrosis-4 (FIB-4) were most used, followed by NAFLD Fibrosis Score, Enhanced Liver Fibrosis, and magnetic resonance elastography. The cutoffs for ruling out significant fibrosis varied considerably between practices and from guidelines, with only 50% using TE <8 kPa, 65% using FIB-4 <1.30 for age <65, and 41% using FIB-4 75% to monitor, and 66% would monitor (intermediate or high risk) annually. Finally, 65% follow professional guideline recommendations regarding NITs. Conclusions: In clinical practice, there is variability in NIT use and their thresholds. Additionally, there is suboptimal adherence to professional societies’ guidelines.
- 30 April 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (5)
Open AccessGlobal patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction–associated steatotic liver disease
Background: Noninvasive tests (NITs) are used to risk-stratify metabolic dysfunction–associated steatotic liver disease. The aim was to survey global patterns of real-world use of NITs. Methods: A 38-item survey was designed by the Global NASH Council. Providers were asked about risks for advanced fibrosis, which NITs (cutoff values) they use to risk-stratify liver disease, monitor progression, and which professional guidelines they follow. Results: A total of 321 participants from 43 countries completed the survey (54% hepatologists, 28% gastroenterologists, and 18% other). Of the respondents, 85% would risk-stratify patients with type 2 diabetes, obesity (82%), or abnormal liver enzymes (73%). Among NITs to rule out significant or advanced fibrosis, transient elastography (TE) and fibrosis-4 (FIB-4) were most used, followed by NAFLD Fibrosis Score, Enhanced Liver Fibrosis, and magnetic resonance elastography. The cutoffs for ruling out significant fibrosis varied considerably between practices and from guidelines, with only 50% using TE <8 kPa, 65% using FIB-4 <1.30 for age <65, and 41% using FIB-4 75% to monitor, and 66% would monitor (intermediate or high risk) annually. Finally, 65% follow professional guideline recommendations regarding NITs. Conclusions: In clinical practice, there is variability in NIT use and their thresholds. Additionally, there is suboptimal adherence to professional societies’ guidelines.
- Open Access
- 17 October 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (10) , e0003714
Mpox: Neglect has led to a more dangerous virus now spreading across borders, harming and killing people. Leaders must take action to stop mpox now
- 17 October 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (10) , e0003714
Open AccessMpox: Neglect has led to a more dangerous virus now spreading across borders, harming and killing people. Leaders must take action to stop mpox now
- Open Access
- 1 February 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (2)
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement
Background: Following the adoption of new nomenclature for steatotic liver disease, we aimed to build consensus on the use of International Classification of Diseases codes and recommendations for future research and advocacy. Methods: Through a two-stage Delphi process, a core group (n = 20) reviewed draft statements and recommendations (n = 6), indicating levels of agreement. Following revisions, this process was repeated with a large expert panel (n = 243) from 73 countries. Results: Consensus ranged from 88.8% to 96.9% (mean = 92.3%). Conclusions: This global consensus statement provides guidance on harmonizing the International Classification of Diseases coding for steatotic liver disease and future directions to advance the field.
- 1 February 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (2)
Open AccessThe future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement
Background: Following the adoption of new nomenclature for steatotic liver disease, we aimed to build consensus on the use of International Classification of Diseases codes and recommendations for future research and advocacy. Methods: Through a two-stage Delphi process, a core group (n = 20) reviewed draft statements and recommendations (n = 6), indicating levels of agreement. Following revisions, this process was repeated with a large expert panel (n = 243) from 73 countries. Results: Consensus ranged from 88.8% to 96.9% (mean = 92.3%). Conclusions: This global consensus statement provides guidance on harmonizing the International Classification of Diseases coding for steatotic liver disease and future directions to advance the field.
- 25 August 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 79 (5) , 1076-1078
Uniting to defeat steatotic liver disease: A global mission to promote healthy livers and healthy lives
- 25 August 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 79 (5) , 1076-1078
Uniting to defeat steatotic liver disease: A global mission to promote healthy livers and healthy lives
- Open Access
- 18 April 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 78 (3) , 911-928
The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories
Background & Aims: Fatty liver disease is highly prevalent, resulting in overarching wellbeing and economic costs. Addressing it requires comprehensive and coordinated multisectoral action. We developed a fatty liver disease-Sustainable Development Goal (SDG) country score to provide insights into country-level preparedness to address fatty liver disease through a whole-of-society lens. Approach & Results: We developed two fatty liver disease-SDG score sets. The first included six indicators (child wasting, child overweight, non-communicable disease [NCD] mortality, universal health coverage service coverage index, health worker density, and education attainment), covering 195 countries between 1990-2017. The second included the aforementioned indicators plus an urban green space (UGS) indicator, covering 60 countries for which 2017 data were available. To develop the fatty liver disease-SDG score, indicators were categorised as “positive” or “negative” and scaled from 0–100. Higher scores indicate better preparedness levels. Fatty liver disease-SDG scores varied between countries (n = 195), from 14.6 (95% UI 8.9–19.4) in Niger to 93.5 (91.6–95.3) in Japan; 18 countries scored > 85. Regionally, the high-income super-region had the highest score at 88.8 (87.3–90.1) in 2017, while south Asia had the lowest score at 44.1 (42.4–45.8). Between 1990-2017, the fatty liver disease-SDG score increased in all super-regions, with the greatest increase in south Asia, but decreased in eight countries. Conclusions: The fatty liver disease-SDG score provides a strategic advocacy tool at the national and global levels for the liver health field and NCD advocates, highlighting the multi-sectoral collaborations needed to address fatty liver disease, and NCDs overall. Export
- 18 April 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 78 (3) , 911-928
Open AccessThe global fatty liver disease Sustainable Development Goal country score for 195 countries and territories
Background & Aims: Fatty liver disease is highly prevalent, resulting in overarching wellbeing and economic costs. Addressing it requires comprehensive and coordinated multisectoral action. We developed a fatty liver disease-Sustainable Development Goal (SDG) country score to provide insights into country-level preparedness to address fatty liver disease through a whole-of-society lens. Approach & Results: We developed two fatty liver disease-SDG score sets. The first included six indicators (child wasting, child overweight, non-communicable disease [NCD] mortality, universal health coverage service coverage index, health worker density, and education attainment), covering 195 countries between 1990-2017. The second included the aforementioned indicators plus an urban green space (UGS) indicator, covering 60 countries for which 2017 data were available. To develop the fatty liver disease-SDG score, indicators were categorised as “positive” or “negative” and scaled from 0–100. Higher scores indicate better preparedness levels. Fatty liver disease-SDG scores varied between countries (n = 195), from 14.6 (95% UI 8.9–19.4) in Niger to 93.5 (91.6–95.3) in Japan; 18 countries scored > 85. Regionally, the high-income super-region had the highest score at 88.8 (87.3–90.1) in 2017, while south Asia had the lowest score at 44.1 (42.4–45.8). Between 1990-2017, the fatty liver disease-SDG score increased in all super-regions, with the greatest increase in south Asia, but decreased in eight countries. Conclusions: The fatty liver disease-SDG score provides a strategic advocacy tool at the national and global levels for the liver health field and NCD advocates, highlighting the multi-sectoral collaborations needed to address fatty liver disease, and NCDs overall. Export
- Open Access
- 22 September 2022
- Published by Elsevier in JHEP Reports
- Vol. 5 (1) , 100596
Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice
- 22 September 2022
- Published by Elsevier in JHEP Reports
- Vol. 5 (1) , 100596
Open AccessReal-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice
- Top Cited PapersOpen Access
- 1 April 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 76 (4) , 771-780
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
- 1 April 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 76 (4) , 771-780
Top Cited PapersOpen AccessThe global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
- Open Access
- 28 January 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (4) , 489-490
Editorial: global liver fat accumulation and global health—towards a sustainable development goal. Authors' reply
- 28 January 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (4) , 489-490
Open AccessEditorial: global liver fat accumulation and global health—towards a sustainable development goal. Authors' reply
- Open Access
- 5 December 2021
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (2) , 234-243
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach
Summary: Background: Non‐alcoholic fatty liver disease (NAFLD) is a highly prevalent condition that requires a comprehensive and coordinated response across sectors and disciplines.Aims: In the absence of a multisectoral framework to tackle this condition, we developed one using the sustainable development goals (SDGs) as the basis for converging thinking about the design and delivery of public health responses.Methods: A multidisciplinary group identified the SDG targets and indicators for inclusion in the new framework through a two‐stage process. Firstly, a core team of three researchers independently reviewed the 169 targets and 231 indicators of the SDGs to select a shortlist. Over two Delphi rounds, a multidisciplinary group of 12 experts selected which of the shortlisted targets and indicators to include. Respondents also provided written feedback on their selection. Targets and indicators with 75% or greater agreement were included in the final framework.Results: The final framework comprises 16 targets—representing 9% of all targets and 62% (16/26) of the shortlisted targets—and seven indicators, accounting for 50% (7/14) of the shortlisted indicators and 3% of all indicators. The selected targets and indicators cover a broad range of factors, from health, food and nutrition to education, the economy, and the built environment.Conclusions: Addressing the challenge of NAFLD will require a re‐envisioning of the liver health landscape, with greater focus on joined‐up systems thinking and action. This new framework can help guide this process, including by outlining the stakeholders with whom the liver health community needs to engage.
- 5 December 2021
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (2) , 234-243
Open AccessA sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach
Summary: Background: Non‐alcoholic fatty liver disease (NAFLD) is a highly prevalent condition that requires a comprehensive and coordinated response across sectors and disciplines.Aims: In the absence of a multisectoral framework to tackle this condition, we developed one using the sustainable development goals (SDGs) as the basis for converging thinking about the design and delivery of public health responses.Methods: A multidisciplinary group identified the SDG targets and indicators for inclusion in the new framework through a two‐stage process. Firstly, a core team of three researchers independently reviewed the 169 targets and 231 indicators of the SDGs to select a shortlist. Over two Delphi rounds, a multidisciplinary group of 12 experts selected which of the shortlisted targets and indicators to include. Respondents also provided written feedback on their selection. Targets and indicators with 75% or greater agreement were included in the final framework.Results: The final framework comprises 16 targets—representing 9% of all targets and 62% (16/26) of the shortlisted targets—and seven indicators, accounting for 50% (7/14) of the shortlisted indicators and 3% of all indicators. The selected targets and indicators cover a broad range of factors, from health, food and nutrition to education, the economy, and the built environment.Conclusions: Addressing the challenge of NAFLD will require a re‐envisioning of the liver health landscape, with greater focus on joined‐up systems thinking and action. This new framework can help guide this process, including by outlining the stakeholders with whom the liver health community needs to engage.